Abstract
The Trk family of neurotrophin tyrosine kinase receptors is emerging as an important player in carcinogenic progression in non-neuronal tissues. Here, we show that breast tumors present high levels of TrkA and phospho-TrkA compared to normal breast tissues. To further evaluate the precise functions of TrkA overexpression in breast cancer development, we have performed a series of biological tests using breast cancer cells that stably overexpress TrkA. We show that (1) TrkA overexpression promoted cell growth, migration and invasion in vitro; (2) overexpression of TrkA per se conferred constitutive activation of its tyrosine kinase activity; (3) signal pathways including PI3K-Akt and ERK/p38 MAP kinases were activated by TrkA overexpression and were required for the maintenance of a more aggressive cellular phenotype; and (4) TrkA overexpression enhanced tumor growth, angiogenesis and metastasis of xenografted breast cancer cells in immunodeficient mice. Moreover, recovered metastatic cells from the lungs exhibited enhanced anoikis resistance that was abolished by the pharmacological inhibitor K252a, suggesting that TrkA-promoted breast tumor metastasis could be mediated at least in part by enhancing anoikis resistance. Together, these results provide the first direct evidence that TrkA overexpression enhances the tumorigenic properties of breast cancer cells and point to TrkA as a potential target in breast cancer therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Adriaenssens E, Vanhecke E, Saule P, Mougel A, Page A, Romon R et al. (2008). Nerve growth factor is a potential molecular target in breast cancer. Cancer Res 68: 346–351.
Aragona M, Panetta S, Silipigni AM, Romeo DL, Pastura G, Mesiti M et al. (2001). Nerve growth factor receptor immunoreactivity in breast cancer patients. Cancer Invest 19: 692–697.
Campos X, Munoz Y, Selman A, Yazigi R, Moyano L, Weinstein-Oppenheimer C et al. (2007). Nerve growth factor and its high-affinity receptor trkA participate in the control of vascular endothelial growth factor expression in epithelial ovarian cancer. Gynecol Oncol 104: 168–175.
Cantarella G, Lempereur L, Presta M, Ribatti D, Lombardo G, Lazarovici P et al. (2002). Nerve growth factor-endothelial cell interaction leads to angiogenesis in vitro and in vivo. FASEB J 16: 1307–1309.
Chao MV . (1994). The p75 neurotrophin receptor. J Neurobiol 25: 1373–1385.
Chiarenza A, Lazarovici P, Lempereur L, Cantarella G, Bianchi A, Bernardini R . (2001). Tamoxifen inhibits nerve growth factor-induced proliferation of the human breast cancerous cell line MCF-7. Cancer Res 61: 3002–3008.
Davidson B, Reich R, Lazarovici P, Ann Florenes V, Nielsen S, Nesland JM . (2004). Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma. Breast Cancer Res Treat 83: 119–128.
Davidson B, Reich R, Lazarovici P, Nesland JM, Skrede M, Risberg B et al. (2003). Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma. Clin Cancer Res 9: 2248–2259.
Descamps S, Pawlowski V, Revillion F, Hornez L, Hebbar M, Boilly B et al. (2001a). Expression of nerve growth factor receptors and their prognostic value in human breast cancer. Cancer Res 61: 4337–4340.
Descamps S, Toillon RA, Adriaenssens E, Pawlowski V, Cool SM, Nurcombe V et al. (2001b). Nerve growth factor stimulates proliferation and survival of human breast cancer cells through two distinct signaling pathways. J Biol Chem 276: 17864–17870.
Dolle L, El Yazidi-Belkoura I, Adriaenssens E, Nurcombe V, Hondermarck H . (2003). Nerve growth factor overexpression and autocrine loop in breast cancer cells. Oncogene 22: 5592–5601.
Douma S, Van Laar T, Zevenhoven J, Meuwissen R, Van Garderen E, Peeper DS . (2004). Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB. Nature 430: 1034–1039.
Frisch SM, Screaton RA . (2001). Anoikis mechanisms. Curr Opin Cell Biol 13: 555–562.
Geiger TR, Peeper DS . (2007). Critical role for TrkB kinase function in anoikis suppression, tumorigenesis, and metastasis. Cancer Res 67: 6221–6229.
Hedley BD, Vaidya KS, Phadke P, MacKenzie L, Dales DW, Postenka CO et al. (2008). BRMS1 suppresses breast cancer metastasis in multiple experimental models of metastasis by reducing solitary cell survival and inhibiting growth initiation. Clin Exp Metastasis 25: 727–740.
Jechlinger M, Sommer A, Moriggl R, Seither P, Kraut N, Capodiecci P et al. (2006). Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Invest 116: 1561–1570.
McGregor LM, McCune BK, Graff JR, McDowell PR, Romans KE, Yancopoulos GD et al. (1999). Roles of trk family neurotrophin receptors in medullary thyroid carcinoma development and progression. Proc Natl Acad Sci USA 96: 4540–4545.
Mercurio AM, Lipscomb EA, Bachelder RE . (2005). Non-angiogenic functions of VEGF in breast cancer. J Mammary Gland Biol Neoplasia 10: 283–290.
Mukai J, Suvant P, Sato TA . (2003). Nerve growth factor-dependent regulation of NADE-induced apoptosis. Vitam Horm 66: 385–402.
Nakanishi K, Sakamoto M, Yasuda J, Takamura M, Fujita N, Tsuruo T et al. (2002). Critical involvement of the phosphatidylinositol 3-kinase/Akt pathway in anchorage-independent growth and hematogeneous intrahepatic metastasis of liver cancer. Cancer Res 62: 2971–2975.
Rennebeck G, Martelli M, Kyprianou N . (2005). Anoikis and survival connections in the tumor microenvironment: is there a role in prostate cancer metastasis? Cancer Res 65: 11230–11235.
Reichardt LF . (2006). Neurotrophin-regulated signaling pathways. Philos Trans R Soc Lond B Biol Sci 361: 1545–1564.
Ricci A, Greco S, Mariotta S, Felici L, Bronzetti E, Cavazzana A et al. (2001). Neurotrophins and neurotrophin receptors in human lung cancer. Am J Respir Cell Mol Biol 25: 439–446.
Sawaki M, Ito Y, Tada K, Mizunuma N, Takahashi S, Horikoshi N et al. (2004). Efficacy and safety of trastuzumab as a single agent in heavily pretreated patients with HER-2/neu-overexpressing metastatic breast cancer. Tumori 90: 40–43.
Shen X, Kramer RH . (2004). Adhesion-mediated squamous cell carcinoma survival through ligand-independent activation of epidermal growth factor receptor. Am J Pathol 165: 1315–1329.
Tacconelli A, Farina AR, Cappabianca L, Desantis G, Tessitore A, Vetuschi A et al. (2004). TrkA alternative splicing: a regulated tumor-promoting switch in human neuroblastoma. Cancer Cell 6: 347–360.
Tagliabue E, Castiglioni F, Ghirelli C, Modugno M, Asnaghi L, Somenzi G et al. (2000). Nerve growth factor cooperates with p185(HER2) in activating growth of human breast carcinoma cells. J Biol Chem 275: 5388–5394.
Ursini-Siegel J, Schade B, Cardiff RD, Muller WJ . (2007). Insights from transgenic mouse models of ERBB2-induced breast cancer. Nat Rev Cancer 7: 389–397.
Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L et al. (2002). Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719–726.
Weeraratna AT, Arnold JT, George DJ, DeMarzo A, Isaacs JT . (2000). Rational basis for Trk inhibition therapy for prostate cancer. Prostate 45: 140–148.
Zhu Z, Friess H, diMola FF, Zimmermann A, Graber HU, Korc M et al. (1999). Nerve growth factor expression correlates with perineural invasion and pain in human pancreatic cancer. J Clin Oncol 17: 2419–2428.
Acknowledgements
We acknowledge the excellent technical assistance of Isabelle Lefebvre. This work was supported by la Ligue Nationale Contre le Cancer (Equipe Labellisée 2009), INSERM, le Ministère de l’Education Nationale and la Région Nord/Pas-de-Calais plus the FEDER.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on the Oncogene website (http://www.nature.com/onc)
Rights and permissions
About this article
Cite this article
Lagadec, C., Meignan, S., Adriaenssens, E. et al. TrkA overexpression enhances growth and metastasis of breast cancer cells. Oncogene 28, 1960–1970 (2009). https://doi.org/10.1038/onc.2009.61
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2009.61
Keywords
This article is cited by
-
Activation of the p53 signaling pathway by piRNA-MW557525 overexpression induces a G0/G1 phase arrest thus inhibiting neuroblastoma growth
European Journal of Medical Research (2023)
-
The phosphorylation of PHF5A by TrkA-ERK1/2-ABL1 cascade regulates centrosome separation
Cell Death & Disease (2023)
-
Characterization of LTr1 derived from cruciferous vegetables as a novel anti-glioma agent via inhibiting TrkA/PI3K/AKT pathway
Acta Pharmacologica Sinica (2023)
-
ProNGF promotes brain metastasis through TrkA/EphA2 induced Src activation in triple negative breast cancer cells
Experimental Hematology & Oncology (2023)
-
PI3K signalling at the intersection of cardio-oncology networks: cardiac safety in the era of AI
Cellular and Molecular Life Sciences (2022)